Northwest Biotherapeutics (NWBO) Interest Expenses (2010 - 2026)

Northwest Biotherapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 46.44% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $9.2 million (up 3844.64% YoY), while the FY2025 annual figure was $8.7 million, down 96.91% from the prior year.
• Interest Expenses for Q1 2026 stood at $2.3 million, down from $2.6 million in the prior quarter.
• The five-year high for Interest Expenses was $114.6 million in Q3 2022, with the low at -$5.1 million in Q4 2024.
• The 5-year median for Interest Expenses is $1.7 million (2023), against an average of $8.1 million.
• The sharpest annual moves came in 2022 and 2023: Interest Expenses jumped 7045.7% in 2022, then sank 558.19% in 2023.
• Northwest Biotherapeutics' Interest Expenses stood at $861000.0 in 2022, then tumbled by 558.19% to -$3.9 million in 2023, then tumbled by 30.52% to -$5.1 million in 2024, then soared by 150.92% to $2.6 million in 2025, then slipped by 10.53% to $2.3 million in 2026.
• Business Quant data shows NWBO's Interest Expenses at $2.3 million in Q1 2026, $2.6 million in Q4 2025, and $2.6 million in Q3 2025.